by Dan Roberts
Ophthotech has begun the first phase of a clinical trial of E10030, an anti-platelet derived growth factor aptamer being developed for treating wet AMD. The trial will evaluate the safety and tolerability of E10030 in combination with an antiangiogenic drug. The hope is that the combination will result in regression of new unwanted blood vessels that have begun leaking into the retina due to neovascularization.
According to Samir Patel, M.D., president and CEO of Ophthotech, E10030 is the first of three compounds, including ARC1905 and volociximab (M200), that Ophthotech is developing to treat AMD.